Podcasts about Genoa

https://thecommunists.org/2025/09/24/news/genoa-dockers-convene-european-conference-non-cooperation-genocide/ This weekend, port worker delegations will meet with workers involved in the direct and/or indirect supply chain of transporting or producing war materials. Dockworkers in the Italian port of Genoa have consistently led the way in obstructing the efforts of the Nato war machine. As well as stopping arms shipments to Israel they have also stopped shipments of munitions to Ukraine and to Saudi Arabia (for use in its genocidal war against Yemen). Their example is one that should be followed by workers everywhere. Subscribe! Donate! Join us in building a bright future for humanity! www.thecommunists.org www.lalkar.org www.redyouth.org Telegram: t.me/thecommunists Twitter: twitter.com/cpgbml Soundcloud: @proletarianradio Rumble: rumble.com/c/theCommunists Odysee: odysee.com/@proletariantv:2 Facebook: www.facebook.com/cpgbml Online Shop: https://shop.thecommunists.org/ Education Program: Each one teach one! www.londonworker.org/education-programme/ Join the struggle www.thecommunists.org/join/ Donate: www.thecommunists.org/donate/

Ripercorriamo le ultime ventiquattro ore di Genoa, in particolare quelli che sono stati gli interventi in conferenza stampa di mister De Rossi a due giorni dalla gara di Cagliari e, ancora, le riflessioni arrivate dall'Assemblea ACG di ieri sera all'IIS. Ne parliamo in puntata. Buoncalcioatutti!

Guest Dr. Rusha Bhandari and host Dr. Davide Soldato discuss JCO article "Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study, " with a particular focus on mortality data, development of secondary malignancies and the importance of education for both patients and healthcare providers regarding long-term follow-up and care. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato: Hello, and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, Medical Oncologist at Ospedale Policlinico San Martino in Genoa, Italy. Today, we are joined by JCO author, Dr. Rusha Bhandari, a Pediatric Hematologist-Oncologist and Assistant Professor in the Department of Pediatrics and Population Science at City of Hope, California. Today, we will be discussing the article titled "Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study." So, thank you for speaking with us, Dr. Bhandari. Dr. Rusha Bhandari: Thanks so much for having me. Dr. Davide Soldato: So, I just want to go straight ahead in the paper and start from the title. So, we heard that you included in this study childhood survivors of pediatric cancer that were aged 50 years or higher. So, this is a very critical life stage when we know that there are a lot of aging-related comorbidities that can happen, also in the general population but potentially specifically in childhood cancer survivors. So, first of all, I wanted to ask you, why this specific study in this very specific population? Because I think that we had already some data in younger survivors, but now we are focusing specifically on patients aged 50 or more. Dr. Rusha Bhandari: Absolutely. So, to answer that question, I'll take a little bit of a step back in terms of where we are now and where we came from in terms of treatment for childhood cancers. So, thankfully, we now have great curative therapies and survival rates for many childhood cancers, including the most common ones. But this was not necessarily the case 50 or more years ago. So, we essentially are now seeing the first generation of older survivors who are 30, 40, or more years from completion of their cancer treatment. As you pointed out, we know from younger survivors that they have a markedly higher risk of malignancies and health conditions than the general population. You don't typically expect to see things like heart disease or diabetes, for example, in a young adult. But the question that remained was what the health status and risk of these conditions are in survivors who are entering this critical age, as you mentioned, 50 or older, when you do start to see these aging-related changes in the general population. And the question is whether we're still observing increased risks related to cancer treatment that was delivered 30 or more years ago in these survivors who are now entering ages 50 and beyond. Dr. Davide Soldato: Thanks so much. You used the data from a study that is called the Childhood Cancer Survivor Study. So, just a little bit of explanation for our listeners. How is the study conducted? What type of data are you collecting? And specifically for the interest of the study that was reported in this manuscript, which outcomes were really important for you and were so evaluated in the manuscript? Dr. Rusha Bhandari: Yes. So, the Childhood Cancer Survivor Study is a really excellent resource that combines information from children who were treated across North America at various different centers and sites. So it gives us a really good understanding of how different survivors are doing as they do progress through their survivorship journey. The Childhood Cancer Survivor Study includes a baseline questionnaire when participants are first eligible or first enter the study, and then includes a series of follow-up questionnaires to really understand how they're doing, like I mentioned, as they progress throughout their survivorship journey. And so for this study, we really wanted to take a global look at how these patients were doing as they entered that older age range. And so we wanted to look at outcomes ranging from mortality through the health conditions that we've seen from other survivorship studies, including subsequent malignant neoplasms, other health conditions, I mentioned earlier heart disease and other comorbidities we know survivors can be at increased risk for, and also things like frailty, which we know is, you know, the most widely recognized phenotype of aging. And we see that earlier on in our younger survivors. We want to see how this translated to these older survivors and then also other health outcomes like their health status. What is their self-report of their physical health, their mental health? Things like that. So we wanted a very comprehensive understanding of their health. Dr. Davide Soldato: This is a very comprehensive study. Right now it includes more than 30,000 patients that have been treated for childhood cancer, but specifically looking at the question of survivors aged 50 years or higher, you included more than 7,000 patients inside of this study. So, looking at the first outcome that you mentioned, which I think it's also one of the most important, you look specifically at mortality, and in this specific population, you saw a striking three-fold increase in mortality when comparing these survivors with the general population. I just wanted to dive in this result and ask you: What do you see as the main driver for this excess mortality in this population of survivors? And as you were mentioning, the study also collects information about the treatment received. So, was there any association with a specific kind of treatment that was received for curing these childhood cancers? Dr. Rusha Bhandari: I agree. I would say it's striking to see that mortality risk among the survivors relative to the general population. And we do know, again from prior studies, that survivors of childhood cancer do have an increased risk of mortality compared to the general population, but I think looking at those curves of the cumulative mortality risk was really quite striking as they diverge, and that's, you know, just so long past their initial diagnosis and treatment. We know that subsequent malignant neoplasms or secondary cancers are a really an important contributor to mortality among survivors. And I think it was important to note that even in these older survivors, it's still such an important contributor to mortality, and I think this really highlights the need for us to better understand what is driving specific secondary cancers and what are the differences in the biology and treatment approaches for some of these cancers? And how might that then be contributing to the mortality risk? Dr. Davide Soldato: Related to the treatment mortalities - because I think that one of the main forces of the study, as it is conducted, is that it contains a lot of information regarding radiotherapy, allogeneic transplant, surgery, type of chemotherapy received by these survivors - so, are we able right now with the data that we have to pinpoint which of these treatments can potentially lead to such increased risk of mortality? Dr. Rusha Bhandari: So, we weren't able to look at the comprehensive treatment exposures and mortality risk for this paper. So that might be one of the questions I would put on the side. We were able to look at that in relation to subsequent malignant neoplasms and health conditions though, as you mentioned. Dr. Davide Soldato: Another thing that I think is very important is that you were able to look at specific causes for mortality. So for example, you mentioned the increased rate of neoplasm in this population and specifically, more or less 7.6% of the patients that were included in the study developed another neoplasm after the ones they were cured for in the childhood period. So, you saw a wide range of cancer, for example, bone and soft tissue sarcomas, breast cancer, genitourinary cancer. And as you were mentioning, there were some associations for treatment modalities that were associated with a higher risk of developing this type of cancer. Can you expand a little bit on this? Dr. Rusha Bhandari: Absolutely. And so the key part here was that we really looked at any of these outcomes that occurred beyond age 50. What we found was there is still an increased risk of secondary cancers beyond that initial childhood cancer diagnosis, but when we really looked at that data, it was specifically among survivors who had a history of receiving radiation. And we did not necessarily see an association between different chemotherapy exposures and secondary cancers. And I think this speaks to what we're now learning in terms of the very long-term effects of radiation and how that impacts ongoing health risk even in patients who are 30 or more years out from their treatment. And I think it really highlights the importance of these- the efforts that have been made in the more recent decades to really try and reduce or eliminate radiation where possible, you know, as we've come to understand more about these long-term effects from it. Dr. Davide Soldato: A clear association with radiation therapy but no association when we look at specific types of chemotherapy that were used for curing this childhood cancer. Another thing that I think it's very interesting and you briefly mentioned before is that potentially when we look at these secondary malignant neoplasm that develop in this situation, we might also see some outcomes that are not comparable to the one of the general population, meaning that we managed to cure less this type of cancer when they develop in these childhood survivors. So, I just wanted to understand if you could provide us with a little bit of perspective also from a clinical standpoint being a pediatric hematologist-oncologist as to why this might be happening and how can we potentially increase the cure rate also in this population of childhood cancer survivors? Dr. Rusha Bhandari: Absolutely. While that was not the focus of this study, it was something that we were certainly interested in is understanding how even once a childhood cancer survivor, for example, develops a health condition or a secondary cancer further into survivorship, how does that outcome then differ from someone in the general population? And there's a lot of interest in ongoing studies actually evaluating that and understanding what are the differences from the initial presentation, biology, the characteristics of that cancer, through how they're treated. So I don't know if we have all of the answers for that quite yet, but you can imagine if someone hypothetically had a history of receiving a lot of anthracycline chemotherapy or already having received a lot of radiation, that might impact what treatment they might receive for that secondary cancer or if they already have other existing comorbidities that need to be taken into consideration. Dr. Davide Soldato: Speaking about comorbidities, you were mentioning in the beginning that one of the focuses of this scientific work was really to try and see whether also this type of adverse health outcomes that can be potentially related to treatments were more frequent among these childhood cancer survivors. So I think that it's very interesting that for this comparison, you were able to use the data from the siblings of the patients who were included inside of the study. So, just a little bit of a comment on why you decided to use this specific methodology, which I think has a very nice touch to it when we look at these outcomes like, for example, diabetes or cardiovascular disease, and in general, do we see an increased number of chronic health conditions among survivors who were treated for childhood cancers? Dr. Rusha Bhandari: Yes, so this is a really excellent strength of the Childhood Cancer Survivor Study is that they have information, longitudinal information, on survivors as well as their siblings. So, you know, when we were discussing the design of the study, I mentioned that we have initial baseline questionnaires as well as multiple follow-up questionnaires, and that is for both the survivors and the siblings. And so we're able to really understand their health course over time. We chose to evaluate sibling data because then you're really able to look at people who have similar characteristics, right? Similar environmental exposures in theory, potentially similar genetic predispositions and makeups and things like that. And so you can really try and have as good of a comparison as possible. Dr. Davide Soldato: Did we see any increase in chronic health condition when looking at survivors compared to the siblings? Dr. Rusha Bhandari: We did. And while that's been reported before, again, I think it's important to demonstrate that in this older population when you would expect that these siblings would now also be starting to develop different health conditions. Dr. Davide Soldato: One thing that was very interesting is that when we look at the coexistence of multiple comorbid conditions and chronic condition in this population, we also see that for some of these survivors, they basically have the same rates of comorbidities as compared to siblings who are potentially 20 years older than them. So I think that there is really that striking point, as you were mentioning before, of accumulation of changes, also physiological changes that can potentially drive a higher frailty index, which was also higher when looking at these survivors compared to their siblings. One outcome that was really not that worse when we look at survivors of childhood cancer was actually mental health. And as I read the paper, it was something that really surprised me a little bit because you would imagine that going through such a harsh diagnosis, such very complex treatment, very early in their life could potentially lead to some worse health outcomes also in terms of mental health over time. But this was not seen. And just a comment on this, because I think it's a very surprising data. Dr. Rusha Bhandari: Yes, I appreciate that question. So, as you mentioned, mental health is such an important issue for patients, both those undergoing treatment as well as those in long-term survivorship. And in our study, we found that survivors were not more likely, as you mentioned, to report poor mental health compared to their siblings. And I think there's a few possible reasons for this. You know, again, this is self-reported data amongst siblings and survivors who survived to at least 50 years of age and completed a questionnaire. And so that is the group of individuals that we were able to evaluate this in, so we have to keep that in mind. But I think our findings may also reflect the resilience of this particular cohort of aging survivors that we included. This finding has been reported in other studies of survivors as well, and so I think it very well may speak to the resilience of the cohort that we're looking at. Dr. Davide Soldato: Going back just a little bit, you mentioned that the majority potentially of these survivors who were included in the current analysis were treated between 1970s and 1980s. So, as you were mentioning before, radiotherapy was seen as a significant contributor to second neoplasm and also to the increase of this chronic health condition. So, do you believe that there is still a role for these survivorship studies as we are approaching treatment modalities where radiotherapy is administered less frequently or with lower doses or omitted at all in the treatment course of these survivors? Dr. Rusha Bhandari: Absolutely. I think you mentioned a very important point, which is these findings are most applicable to the patients who were included in this cohort or similar cohorts, those who were treated in the 1970s and 80s who now are 50 years or older at this point in time. And as you know, treatment modalities have really changed. You know, as you mentioned, we'll use less radiation in many cases whenever possible, but there are so many new modalities, so many different chemotherapeutic agents, immunotherapy. There's so much more we need to learn about the long-term effects of some of these newer treatment modalities. And also, we've been able to really intensify our treatment regimens with improvements in both treatment approaches and supportive care. And so I think we have a lot to learn about those late effects, and ongoing studies are certainly needed as we continue to have this growing population of older survivors. Dr. Davide Soldato: And now a more general question which builds on the results of the study but goes a little bit beyond what was the scope of the research. So we have just discussed that there is an excess mortality in general, there is a higher risk for secondary malignancies in this population, we see higher accumulation of chronic comorbid conditions that need to be treated. So building on these results, in your opinion, what would be the best framework to follow up these patients over time? Because I imagine that for some of these patients who have been treated 30, 40 years before the moment where we see this type of events, they can be potentially also discharged from more specialistic medical care. So what is the best course of action? Should we keep all of these patients under observation in a very specialistic environment under the care of the oncologist or the pediatric oncologist? Should we create a stronger bond with general practitioners so they know that there is this problem? Dr. Rusha Bhandari: Yes, I mean, I think you're reading my mind. We thankfully do have evidence-based guidelines. We utilize the Children's Oncology Group Long-Term Follow-Up Guidelines, which include screening recommendations for secondary cancers, chronic health conditions, everything based on the underlying diagnosis and treatment that these patients received. But we recognize that a large proportion of these survivors do not continue to have lifelong follow-up at a survivorship center, but really do need that specialized screening based on their treatment that they received. And I think for that reason, it's so important that we continue to build relationships with their primary care providers and really make sure that both patients and their providers have this information at hand regarding what their treatment is and what the screening is that they need and that we be able to have this community whereby we are able to help inform the screening in our own survivorship clinics, but also help guide some of the primary care providers who are going to be seeing these patients in the long run. Dr. Davide Soldato: Do we have any data showing what is the adherence rate of these patients to this type of continuous screening and monitoring over time? Because I imagine that that might also be a point for improvement in terms of quality of care. Can we retain as much childhood cancer survivors as we want as we are learning that there are all these potential negative health outcomes over time? Dr. Rusha Bhandari: We definitely within the survivorship community do want to help make sure as many survivors as possible are being engaged, again, whether it's at their specific cancer center or whether it's in the community, recognizing that for many reasons, it's not feasible to always return to that cancer center for your regular survivorship care. I think there's a lot we can do. Going a little bit outside the scope of your question, but I think there's a lot that we can do nowadays in terms of telehealth and being able to communicate with patients and their providers even if they're geographically not located right near us. But we do have data that shows that the further out many patients get from their initial diagnosis and treatment, the less often they might follow up with a survivorship provider. Some of this varies by different treatment. Dr. Davide Soldato: So, basically the final question is that we need more education and potentially more resources for survivorship clinics and in general to better inform patients and providers about these potential long-term outcomes. Dr. Rusha Bhandari: That's certainly a focus of our survivorship program, for example, is to make sure that we're able to educate patients, inform them of their risks, and why certain screening tests are recommended at certain times in their survivorship journey. And then I think again, thankfully nowadays with all of the electronic medical records and different methods for us to communicate, there's a lot of opportunity for us to continue building these relationships with those primary care providers and making sure they have the information at their fingertips as well as to be able to work in conjunction with these patients to continue to formulate their plans and carry out these screenings and then again, like I was saying, have an easy open line of communication with the oncology centers if they do have any questions. Dr. Davide Soldato: Thanks so much. This brings us to the end of this episode. I would like to thank again Dr. Bhandari for joining us today. Dr. Rusha Bhandari: Thank you so much. It's been a real pleasure speaking with you. Dr. Davide Soldato: And we appreciate you sharing more on your JCO article titled "Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Mister De Rossi, che domani interverrà in sala stampa, attende il rientro degli ultimi nazionali prima di serrare i ranghi e partire direzione Cagliari. Vediamo quali sono le ultime da Pegli in questo mercoledì. Buoncalcioatutti!

Join Matt and Jake as they run you through the latest Serie A Matchday before the International Break broke out, and listen to their thoughts on the latest managerial appointments in the Serie A!Timestamps00:00 Intro and Updates 2:31 Matchday 11 1:19:00 Vanoli's Fiorentina 1:24:53 Palladino's Atalanta 1:47:06 Wisdom With the Wank 1:54:08 Pride of Indonesia 1:58:11 De Rossi's Genoa 1:57:15 OutroBecome a patreon: ⁦https://patreon.com/Serieaspotlight?⁩utm_medium=unknown&utm_source=join_link&utm_campaign=creators hare_creator&utm_content=copyLinkSpecial Shoutout to our Media Partners Benevo Bid - Check out their collection here; ⁦https://benevobid.com/⁩#acmilan #inter #juventus #torino #napoli #atalanta #bologna #fiorentina #roma #lazio #lecce #cagliari #udinese #monza #venezia #como #hellasverona #parma #empoli #genoa #football #soccer #footballpodcast #podcast PatreonYoutube: ⁦https://www.youtube.com/@serieaspotlight⁩Instagram: ⁦https://www.instagram.com/serieaspotlight/⁩Twitter: ⁦https://x.com/SerieASpotlight?⁩

TECH CLUBBERS PODCAST W/ DUB TALES Dub Tales is a solo project by Francesco Vacca, born from the trio Get Serious, active since 2010 with Stefano Cibabene and Michele Quagliati. Starting his DJ career in Genoa in 2006, Francesco co-founded Groove Secret Events, organizing open-air parties with guest artists. In 2008 and 2009, the trio performed at notable Italian clubs like KAMAKAMA ( Viareggio ) and Tenax ( Florence ), gaining exposure beyond their hometown. In 2010, they moved to Berlin, playing in venues such as Sisyphos, Suicide Circus, and securing a residency at Tresor. With Dub Tales, Francesco explores deeper, dub-influenced and ambient techno, drawing inspiration from Detroit's soulful roots that first sparked his musical journey. Follow DUB TALES here: Instagram: https://www.instagram.com/dub_tales Soundcloud: https://soundcloud.com/dub_tales-952900653

Il punto dall'allenamento di oggi, il primo a porte aperte della gestione De Rossi. Dalle indicazioni alle ultime dall'infermeria. Buoncalcioatutti!

When Sydney Sweeney said "Jeans are not Controversial" Mrs. P had to investigate and what she found was astounding. From Sydney Sweeneys stalling career, to her plans with Geoff Bezos,  to the origins of Jeans in India, Britain, America. And how they were touched by the republic of Genoa, the British Ra, East India Trading Company, Mahatma Gandhi, and the prison industrial complex. And then of course back to Sydney Sweeneys GQ interview. GET THE MISCELLANEOUS IMMORALITY SHIRT HERE:

Phyllis seduces Cane; Noah and Sienna’s affair; Adam plans to humiliate Billy; Mariah shuts Tessa out; and The return of Pietro! Visit https://www.yrchat.com to chat with fun and friendly fans of The Young and the Restless. THIS WEEK: Ali’s Y&R Recap, The Weekly Y&R Polls, a “Who Said It” Quote Game, and Opening “The Chatterbox” […]

On November 12th, McHenry Police received a call that a truck hit a curb and a sign. SHAW LOCAL reports officers found 58-year-old James R. Conaway of Genoa asleep behind the wheel of the truck. According to information filed in McHenry County court, Conaway was charged with aggravated DUI, and a judge cited Conaway's history of alcoholism, when he denied Conaway's pretrial release from county jail.

On November 12th, McHenry Police received a call that a truck hit a curb and a sign. SHAW LOCAL reports officers found 58-year-old James R. Conaway of Genoa asleep behind the wheel of the truck. According to information filed in McHenry County court, Conaway was charged with aggravated DUI, and a judge cited Conaway's history of alcoholism when he denied Conaway's pretrial release from county jail.

On November 12th, McHenry Police received a call that a truck hit a curb and a sign. SHAW LOCAL reports officers found 58-year-old James R. Conaway of Genoa asleep behind the wheel of the truck. According to information filed in McHenry County court, Conaway was charged with aggravated DUI, and a judge cited Conaway's history of alcoholism, when he denied Conaway's pretrial release from county jail.

On November 12th, McHenry Police received a call that a truck hit a curb and a sign. SHAW LOCAL reports officers found 58-year-old James R. Conaway of Genoa asleep behind the wheel of the truck. According to information filed in McHenry County court, Conaway was charged with aggravated DUI, and a judge cited Conaway's history of alcoholism when he denied Conaway's pretrial release from county jail.

On November 12th, McHenry Police received a call that a truck hit a curb and a sign. SHAW LOCAL reports officers found 58-year-old James R. Conaway of Genoa asleep behind the wheel of the truck. According to information filed in McHenry County court, Conaway was charged with aggravated DUI, and a judge cited Conaway's history of alcoholism, when he denied Conaway's pretrial release from county jail.

On November 12th, McHenry Police received a call that a truck hit a curb and a sign. SHAW LOCAL reports officers found 58-year-old James R. Conaway of Genoa asleep behind the wheel of the truck. According to information filed in McHenry County court, Conaway was charged with aggravated DUI, and a judge cited Conaway's history of alcoholism when he denied Conaway's pretrial release from county jail.

Il Genoa ha concluso oggi la settimana di allenamenti e riprenderà martedì agli ordini di mister De Rossi, in una settimana che vedrà non solo la conferenza pre Cagliari, ma anche un'assemblea indetta dall'ACG con l'Avvocato D'Angelo. Parliamo di tutte le ultime notizie di casa rossoblù in puntata. Buoncalcioatutti!

Get ready for a Christmas classic like you've never seen it before! Ebenezer Scrooge's Big Genoa Christmas Show transforms Dickens' timeless tale into a hilarious, music-filled celebration of community and holiday spirit, set right here at the Genoa Civic Theatre.Written by Gordon Greenberg and directed by Jeremiah Tudor, this gut-busting, family-friendly production weaves local Genoa touches, familiar faces, and festive fun into a night you won't want to miss.Catch Ebenezer Scrooge's Big Genoa Christmas Show live on December 5, 2025, from 7:30–9:30 PM at the Genoa Civic Theatre.Get your tickets here: genoacivictheatre.com/event-details/ebenezer-scrooges-big-genoa-christmas-show-12-07-2025

Guest Dr. Sundar Jagannath and host Dr. Davide Soldato discuss JCO article "Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma," and the efficacy of CAR-T cell therapy in patients with heavily pretreated RRMM (relapsed/refractory multiple myeloma). TRANSCRIPT Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO author, Professor Sundar Jagannath, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and the Tisch Cancer Institute. He also serves as Network Director for the Center of Excellence for Multiple Myeloma, and he is an internationally recognized expert in the field of multiple myeloma. Today, we will be discussing the article titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." Thank you for speaking with us, Professor Jagannath. Dr. Sundar Jagannath: Thank you for having me, Dr. Davide Soldato. It is a pleasure to be here. JCO is a highly recognized journal among the oncologists, so I am very happy and privileged to be here today. Dr. Davide Soldato: Thank you so much for being with us. So, I wanted to start a little bit with the rationale of the study and the population that was included in the study. So, the trial that we are discussing, CARTITUDE-1, was already published before, and we observed very good results with a single infusion of cilta-cel. So we had previously reported a median progression-free survival of 30 months, and median overall survival was not reached. So, I just wanted to ask you if you could guide us a little bit into the population that was included in the study and also explain a little bit to our listeners what is the drug that we are discussing, cilta-cel. Dr. Sundar Jagannath: It is a CAR T-cell. This is a patient's own lymphocytes, which goes through apheresis and is sent to the company, where they modify it and introduce the B cell receptor. In this case, you know, there is a heavy chain gene receptor for the BCMA, and in cilta-cel, there are actually two receptor sites on each molecule, or there are two binding domains on each receptor molecule. So, it is considered to be quite efficacious. As you reported, the earlier results that the patients who participated, 97% of the patient responded. Now, you asked about the patients who participated in the clinical trial. This clinical trial was conducted between July of 2018 and October of 2019. At that time, this was a phase 1b/phase 2 trial, and the whole idea was to take patients who had relapsed all the available treatment regimen so that these patients were considered to have, in the unmet medical need situation. So, what does that entail? That means the patient should have been exposed to a proteasome inhibitor, to an immunomodulatory molecule, and to an anti-CD38 monoclonal antibody and should have received at least three or more prior lines of therapy and should be actually progressing on their last line of therapy. So with that requirement, if you look at it, the median number of prior therapy on the patients who participated was actually six. So patients were heavily pretreated. They had exhausted all available treatment options. So, they can participate in this clinical trial. And if not, there have been real-world evidence, such as LocoMMotion, which had reported what is the outcome for such a patient if they were treated outside of this clinical trial, if they were treated with the then available regimen. Their median progression free survival would have been only 3 months, and most patients would have lost their life within a year. So, this was truly an unmet medical need with patients in a very difficult clinical situation. Let's put it that way. So, those were the patients who participated in this particular trial. Dr. Davide Soldato: Thank you very much. And as we mentioned before, the results that were obtained in this clinical trial were really very interesting. And now, in this issue of the Journal of Clinical Oncology, you are reporting data with a longer follow up. So we are actually at more than 5 years of follow up for the patients included in this trial. So, I just wanted a little bit of insight into why you decided to report these long-term outcomes and what type of information do you think you could provide with this study to the medical community? Dr. Sundar Jagannath: This is very important because this was a clinical trial that was done in patients who were, as I said, in unmet medical need. Most of the patients had prior stem cell transplantation, had gone through a proteasome inhibitor. Many of them have had both Velcade and carfilzomib treatment. Most of them had been exposed to lenalidomide and pomalidomide. And as required, all of the patients had to have had prior exposure to anti-CD38 monoclonal antibody or daratumumab. So, the patients were heavily pretreated. Typically, TIL CAR T-cells came into the field at this particular moment, until then, we were developing small molecules, and they usually would have a PFS of 3 months and median life expectancy of a year, the overall response rate of 30%, and that is how, if you look back, that is how carfilzomib was approved, that is how pomalidomide was approved. So, the drugs which were approved, including daratumumab, you know, the response rate was in the same ballpark. So you would see that most agents, single agents, would have had a response rate in the neighborhood of 30%, the progression-free survival would have been between 3 to 5 months or 6 months at the most, and the life expectancy was short. And here comes a drug, and when I was following the patients at Mount Sinai, I found that there were a subset of patients, they got one-time treatment and they were in complete remission, no trace of cancer with annual evaluation with PET CT and bone marrow evaluation for MRD. So, I said this is remarkable, and this needs to be reported. And I went to the Janssen and company, and they agreed to review the entire experience. This is remarkable that 32 of the 97 patients, or one third of the patients, were alive and progression-free. This is unheard of for any clinical trial until now, that the patient will be progression-free, one third of the patients on a clinical trial will be progression-free, in the late stage of their disease. So that is the most important impact. And that is why this 5-year follow-up results were presented. Dr. Davide Soldato: Thank you very much. That was very clear. And as you said, we are speaking about a population that was heavily pretreated, that had exhausted all type of treatment options outside of a clinical trial. And as you said, one third of the patients was alive and progression-free after 5 years from being included and infused inside of the study. So, considering this population that, as we said, had received all treatment options, I was wondering if you observed any kind of differences in terms of disease characteristics when looking at these patients that had exceptional response, so, alive and progression-free at 5 years, and the patients that sadly had developed a progression after the infusion in the study. Dr. Sundar Jagannath: This is very important because we wanted to see who are the patients who are having this exceptional outcome. And we looked at all the 97 patients. If we look at all the patients, we saw that there were initially, out of the 97, 17 patients died earlier in the disease course due to treatment related complications, etc. But there were about 46 patients who had progression of disease and 32 patients, or one third, were alive without progression of disease. Then we looked at the 46 patients who had progression of disease. Of them, we found that 30 had disease progression and its complication, and there were actually 13 patients who were still alive even after progression of disease. So we decided to compare these 46 patients who had progression of disease versus 32 patients who had no progression of disease to see what is the difference. To our surprise, the age was similar, male, female distribution was similar. High-risk cytogenetics, which we would have thought, you know, that is why we say high-risk disease, the term, high-risk cytogenetics was equally distributed. That was really a surprise. Number of lines of prior therapy, number of exposure to drugs, all of that was the same. So that was also interesting. But a theme did emerge. Patients, in general, tend to have lower burden of disease who had the exceptional outcome. But there is one which we considered as bad, the extramedullary disease. Multiple myeloma being a blood cancer, it is usually in the bone marrow. When it starts growing outside of the bone marrow, the extramedullary disease, usually it portends poor prognosis. But we were surprised that actually there were an equal number of extramedullary disease patients even in the long-term survivor as those who had progressed of disease. So the most important takeaway was patients who had lower burden of disease, they had less number of myeloma cells in their bone marrow, percentage wise, and the soluble BCMA level was lower. Soluble BCMA is an indirect measure of the amount of plasma cells in the patient's body. It is like a tumor burden. So they were low. So, this was an important finding because it has future ramification, as you can understand. If this treatment is made available earlier in the disease course of the patients, where we are able to control the disease better, then more patients are likely to have such wonderful outcomes as one third of the patient experience in the late stage of the disease. Dr. Davide Soldato: So, you already mentioned soluble BCMA as a marker of potentially better prognosis as being correlated to a lower volume of disease. I was wondering if you could give us some more information about the biomarkers that you evaluated in the study. For example, you evaluated a little bit the CAR T expansion kinetics and also some others that I think could be interesting and could point to some population that experienced such important benefit. Dr. Sundar Jagannath: That is a very important point because CAR T-cell, it is a live cell and its efficacy depends upon how well the CAR T-cell is going to function. And then, you know, the patient undergoes apheresis. This is a patient's own lymphocyte. So first and foremost is who would generate good CAR T-cell. Those who have plenty of lymphocytes at the time they are coming for apheresis. This is likely to happen earlier in the course of the disease than in patients who have gone through numerous lines of therapy and exhausted. So, in this particular trial, of course this was in late stage of the disease, and so we were able to show patients who had lower number of T cell in circulation, and the way to measure is if they had more neutrophils and less lymphocytes. So that is what is called as a higher T cell over neutrophil, they did better. If they have more neutrophil than T cells, then they did not do well. So, procurement. The second one is also whether the T cells are more naive, you know, not exhausted T cells. So more naive T cells, if you are able to procure from the patient, they did very well. Now, after the CAR T-cell manufacture, then the expansion, when you put it back into the patient, if the T cells expand very well, so that the effector, that is the CAR T-cells to the tumor ratio is good, so there are more effector cells, the CAR T was able to expand and the amount of tumor was less, then the efficacy was very, very good. As I said, the patients in this group, those who had a lower burden of disease, they did better, and that is because of the CAR T-cell expansion, so the effector to the target ratio was favorable. So that is another important. And then there are also the type of CAR T-cells, having CD4 T cells with central memory phenotype at the peak expansion also makes a difference. So all of that matters. But this is important because the efficacy of the CAR T-cell, it is persistent, long persistent and keeping the cancer down. Its ability to get rid of the cancer completely at the first go around because usually we are not able to detect the CAR T-cells beyond 6 months in the majority of patients and very rarely after a year or two. So it is very uncommon to find the CAR T-cells in circulation or even in the regular bone marrow evaluation. So, efficacy, the expansion, having naive T cells, having good effector to target ratio and more central memory kind of T cell, because if it is all effector T cell, they will get quickly utilized and get exhausted, whereas the central memory cells can expand more and give more effective CAR T-cells. Dr. Davide Soldato: Thank you very much. I was wondering if you could guide us a little bit into what is your opinion regarding the positioning of CAR T-cells given all of these logistics that is necessary compared, for example, with bispecific antibodies against BCMA, which have the same target, but they do not have all of these logistics before being administered to the patient. Dr. Sundar Jagannath: That is a very important question, how to sequence these treatments now that we have two BCMA-directed CAR T-cells available. We have three BCMA-directed bispecific and one GPRC5D-directed bispecific antibodies are available. And so the question comes in for at least the currently approved CAR T-cell therapy, there is an obligatory time. You have to go through apheresis and you have to ship to the company, and there is a manufacturing time, roughly about 2 months before they can receive it. During that time, you want to make sure the patient's disease is under control. So that is a given. There are several ways to look at it when we evaluate the patient and talk to the patient. One good thing is now the two CAR T-cells which are approved, one is cilta-cel we talked about, and the other one is ide-cel. Ide-cel is approved in earlier line of therapy, two or more prior lines of therapy, and cilta-cel is approved in patients who have failed one line of therapy and who are lenalidomide refractory. So, the treatment of CAR T-cell is available earlier. And as I said, when you administer CAR T-cell earlier, you are able to keep the disease burden down, and it is a one and done deal. There is a better quality of life for the patient, and you are able to produce long, durable remission and potentially a cure. Now coming to the bispecific, they are currently available in later lines of therapy. So if you look at it from a patient's perspective, you can use the CAR T-cell earlier and then go through the bispecific therapy. But if the patient comes with relapsed refractory myeloma and has not used the CAR T-cell therapy and has not used the bispecific therapy, then the physicians have to decide which one they want to use. If somebody's disease is rapidly progressing and they need immediate tumor reduction and they have already exhausted all available therapy, then going through BCMA bispecific therapy is quite appropriate. And secondly, CAR T-cell therapy is generally given to somewhat physically more fit patients, whereas bispecific therapy, because you are giving antibody at step-wise dosing in this patient, and you have the ability to stop at any particular dose and then come back and redose, whereas CAR T is, you just give it to them one time, you have a lot more control. So intermediate frail or even frail patients can go through bispecific therapy, whereas it would not be in the best interest of the patient to go through a CAR T-cell therapy when they are frail. So that is another important point. But from the information available, when the patient goes on a BCMA bispecific therapy and they start progressing on treatment, usually it is their T cells are exhausted or the BCMA is no longer expressed on the tumor cells. So coming with CAR T-cell later on is usually not effective, whereas giving CAR T-cell earlier, if the patient relapses later, they have good T-cell function and most of the time the BCMA is still expressed. So you are able to give the BCMA to the maximum benefit by using the CAR T first and BCMA later. So if somebody asked me how to sequence this, just off the bat, you will say CAR T first, BCMA bispecific second. But as I said, there are unique situations. Then there is another potential that is happening. You can change the target. You can use a BCMA against GPRC5D to reduce the tumor, and then go ahead and consolidate it with a CAR T-cell therapy. That is also possible. You are changing the target from GPRC5D to BCMA, the tumor is already down, so the patient is likely to benefit. So these are all newer treatment options which have become available to the physician. So they will have to look at individual patients and decide what is the best course of action for that patient. Dr. Davide Soldato: So, I just wanted to close a little bit with your opinion about how these results translate into clinical practice. So considering this outstanding 5-year data that we have seen, one third of the patients who are alive and progression-free after a single infusion of cilta-cel, do you think that we could start to think about functional cure even in patients who have a diagnosis of relapsed refractory multiple myeloma? Dr. Sundar Jagannath: My feeling is this is important because in this particular study which is published, 12 patients who were followed at Mount Sinai out of the 32 patients who are alive and progression-free, 12 were followed at Mount Sinai. And they were evaluated every year with bone marrow MRD testing by clonoSEQ in 11 of the 12 patients, and one was by multiparametric flow cytometry. So most of them were 10 to the minus 6, not even one in a million cancer cells, and all of them had functional imaging, which is called PET CT every year. So these were patients who had no evidence of disease that we could detect with the technology available today, serologically, in the bone marrow, or anywhere else in the body with a PET CT. They were found to be disease free after a single infusion of cilta-cel. So, that would be almost to the definition of a cure because if you look at cure as a definition for any cancer, cure is defined as a state of complete remission with no trace of cancer that persists over a period of 5 years or longer without maintenance. And that will be applicable for breast cancer, lymphoma, leukemia. So it is a general statement. And if we use that in myeloma too, then I could say that these 12 patients from my center, we proved that they are cured of their myeloma. They are not functionally cured. You've got to remember, there is only cure. That was the definition across all diseases. So there is nothing like a functional cure. They are cured of myeloma. So is myeloma curable? This is the first time we are looking at that. We do know, every physician treating myeloma that there are patients out there, 10 year and beyond, without evidence of disease. This has been published by University of Arkansas, Bart Barlogie's group, who has been saying that myeloma is a curable disease for a long time. And many others have shown long-term follow up. But this one in a late stage disease, we were able to show that they were one treatment with no maintenance. All other studies have been in newly diagnosed myeloma patients. Nobody has shown in late relapse patients on a clinical trial a third of the patient will be progression-free. And 12 of them who were studied were actually disease free. So they were cured of the disease. So if we accept that, then the next question is, first step towards cure is achieving complete remission. They should have no monoclonal protein by any technology you want to use, no measurable residual disease using next gen sequencing or clonoSEQ, and functional imaging whole body PET CT or whole body MRI. So that is important, definition of the complete remission. And then it has to be sustained. That is something the IMWG and IMS, International Myeloma Society, they will have to come together for a consensus. How many years should they be followed and should be in this kind of status with no trace of cancer? Is it, 3 years are enough? 4 years enough? 5 years is enough? For me, I said in this paper, 5 years is a good definition for achieving a potential cure. Then you use the term 'functionally cured'. I have a problem with functionally cured and operationally cured or whatever. Functionally cured was originally put out by Paiva from Spain. There were 8% of newly diagnosed myeloma patients who have, after they go get treated, they will have an MGUS like phenomenon, a small amount of paraprotein detectable, and they are only 8%. And he said that these patients could be off treatment and the disease does not progress. But the problem is when you are giving treatment like maintenance therapy continuously until progression, you do not know exactly who is in the MGUS situation. So you have to have done sophisticated flow cytometry like Paiva did, and it is not quite clinically applicable. So functionally cured applies only for 8% of the people, so it should go out of the vocabulary. Then you can say 'operationally cured'. These are the patients traditionally Bart Barlogie and others showed that they have a large number of patients who have been followed for 10 years with no recurrence of disease, not on treatment. But in those days, they did not have MRD PET CT and all of them done systematically. So that is why they had to come up with a situation where they said they were operationally cured. So yes, myeloma patients have been cured since auto transplant was introduced. I completely agree. It is not new to the CAR T-cell therapy. But the beauty of the CAR T-cell therapy was it was in relapsed refractory myeloma, unmet medical need, number one. Number two, they were studied systematically. It was a clinical trial adjudicated by FDA and EMA for drug approval, cilta-cel was approved. So these patients were carefully followed, and it was a multi-center study. And in that group of patients, we were able to show patients- So, I think this would indicate cure is a reality in myeloma, and as these kind of treatments, immunologic treatment, either it is a CAR T-cell therapy or BCMA bispecific or whatever, there is a chance more patients are likely to be cured, and these treatments have to move forward and so that we are looking towards a cure. That is the beauty of it, and I just thank you for asking and also throwing in this so-called functionally cured, which people like to use casually, and I say it is time to talk more cure and not stuck with functionally cured because that does not allow the field to progress. Dr. Davide Soldato: Thank you very much. That was very interesting. Dr. Sundar Jagannath: And provocative. Dr. Davide Soldato: A little bit, but I think that we needed to close the podcast with this kind of reflection coming from someone who is an expert in the field, as you are. So, I really wanted to thank you for joining us today and for sharing more on your article, which is titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." If you enjoy our show, please leave us a rating and a review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. Dr. Sundar Jagannath: Thank you. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Mister Daniele De Rossi, incassato il "buon lavoro" della tifoseria organizzata, ha ripreso ieri a lavoarre a Pegli tra nove nazionali lontani da Genova, quattro giocatori indisponibili e una ricerca continua del migliore assetto tecnico per valorizzare gli elementi in rosa. Analizziamo l'attuale situazione in casa rossoblù a nove giorni dalla gara col Cagliari. Buoncalcioatutti!

Au sommaire de Radio Foot Internationale, ce lundi 10 novembre 2025 (16h10 & 21h10 TU) : Liga, le Barça revient ; Serie A, le Napoli stoppé par Bologne, l'AC Milan freiné à Parme, la Roma de Gasperini et l'Inter en profitent pour se hisser en tête ; Platini : « Coups francs, bouclettes et petit short ». Liga, le Barça revient. Toujours sur le fil défensivement, les Blaugranas sont allés chercher une victoire importante sur le terrain du Celta Vigo (4-2). Yamal buteur, retour gagnant de Lewandowski avec un triplé, pour sa première titularisation depuis un mois. Défense fragile, attaque moins efficace ? Le Real Madrid et ses limites. Atone dans le derby contre le Rayo Vallecano, Mbappé muet, fin de série pour le Kyks, qui n'a pas eu de ballons à exploiter. Catalans et Merengues, animateurs habituels du championnat à la mécanique enrayée. L'Atlético sous pavillon américain. Le fonds d'investissement Apollo Sports Capital devient le nouvel actionnaire majoritaire du club. Les Colchoneros entrent dans une nouvelle dimension financière, des ambitions sportives redéfinies ? Serie A, le Napoli stoppé par Bologne, l'AC Milan freiné à Parme, la Roma de Gasperini et l'Inter en profitent pour se hisser en tête. Deuxième saison d'Antonio Conte sous le Vésuve, l'agacement de l'ex de l'Inter et de la Juve est perceptible, surtout après la claque reçue à Eindhoven en C1. Il exhorte ses joueurs à retrouver l'état d'esprit de la saison passée. Par ici la sortie : Vieira remercié par le Genoa, l'Atalanta se sépare de Juric. La Dea, place forte du championnat, végète à la 13e place. Platini : « Coups francs, bouclettes et petit short ». C'est le titre du livre publié par So Foot et les éditions Marabout, sur un autre « 10 » de légende, à l'occasion des 70 ans du milieu de terrain. Retour sur la carrière de l'ex-capitaine des bleus, et élégant joueur de la Juve. Le foot aux footballeurs aussi. Platoche nourrit le projet d'un musée du foot ouvrier à Jœuf, sa ville natale. Pour débattre avec Annie Gasnier : Chérif Ghemmour, Étienne Moatti et Éric Rabesandratana. Technique/Réalisation : Laurent Salerno --  David Fintzel/Pierre Guérin.

Au sommaire de Radio Foot Internationale, ce lundi 10 novembre 2025 (16h10 & 21h10 TU) : Liga, le Barça revient ; Serie A, le Napoli stoppé par Bologne, l'AC Milan freiné à Parme, la Roma de Gasperini et l'Inter en profitent pour se hisser en tête ; Platini : « Coups francs, bouclettes et petit short ». Liga, le Barça revient. Toujours sur le fil défensivement, les Blaugranas sont allés chercher une victoire importante sur le terrain du Celta Vigo (4-2). Yamal buteur, retour gagnant de Lewandowski avec un triplé, pour sa première titularisation depuis un mois. Défense fragile, attaque moins efficace ? Le Real Madrid et ses limites. Atone dans le derby contre le Rayo Vallecano, Mbappé muet, fin de série pour le Kyks, qui n'a pas eu de ballons à exploiter. Catalans et Merengues, animateurs habituels du championnat à la mécanique enrayée. L'Atlético sous pavillon américain. Le fonds d'investissement Apollo Sports Capital devient le nouvel actionnaire majoritaire du club. Les Colchoneros entrent dans une nouvelle dimension financière, des ambitions sportives redéfinies ? Serie A, le Napoli stoppé par Bologne, l'AC Milan freiné à Parme, la Roma de Gasperini et l'Inter en profitent pour se hisser en tête. Deuxième saison d'Antonio Conte sous le Vésuve, l'agacement de l'ex de l'Inter et de la Juve est perceptible, surtout après la claque reçue à Eindhoven en C1. Il exhorte ses joueurs à retrouver l'état d'esprit de la saison passée. Par ici la sortie : Vieira remercié par le Genoa, l'Atalanta se sépare de Juric. La Dea, place forte du championnat, végète à la 13e place. Platini : « Coups francs, bouclettes et petit short ». C'est le titre du livre publié par So Foot et les éditions Marabout, sur un autre « 10 » de légende, à l'occasion des 70 ans du milieu de terrain. Retour sur la carrière de l'ex-capitaine des bleus, et élégant joueur de la Juve. Le foot aux footballeurs aussi. Platoche nourrit le projet d'un musée du foot ouvrier à Jœuf, sa ville natale. Pour débattre avec Annie Gasnier : Chérif Ghemmour, Étienne Moatti et Éric Rabesandratana. Technique/Réalisation : Laurent Salerno --  David Fintzel/Pierre Guérin.

An old Venezia favourite was installed as Fiorentina's new manager, but he couldn't guide them to victory against Genoa, while Inter and Roma climbed to the top of the table. Plus, Conte's second season struggles and Milan's Allegriball cost Napoli and the Rossoneri. Hosted on Acast. See acast.com/privacy for more information.

Scarica Revolut gratis con il mio link per ricevere un bonus di benvenuto di €20*: https://get.revolut.com/e9Jc/podcast1*Si applicano condizioni minimeUndicesima giornata di Serie A in archivio, con due squadre al comando, Inter e Roma, e le altre che inseguono. Scivolone Napoli e Atalanta, inizia con un pari l'avventura di De Rossi e Vanoli, finisce a reti bianche il derby della Mole tra Juventus e Torino. Ne parlano a Potrero Angelo Taglieri, Enrico Zambruno e Simone Indovino. Potrero, dove tutto ha inizio. Un podcast sul calcio italiano e internazionale. Su Como TV (https://tv.comofootball.com) nel 2025 potete seguire in diretta e gratuitamente le partite della Saudi Pro League, Saudi King's Cup, Supercoppa d'Arabia, Copa Libertadores, Copa Sudamericana, Recopa, Liga Profesional Argentina, Trofeo de Campeones argentino, Eredivisie, Coppa di Francia, Scottish Premiership, Coppa di Scozia, Scottish League Cup, Scottish Championship, Coppa di Portogallo, Supercoppa di Portogallo, HNL croata e tutti i contenuti di calcio italiano e internazionale on demand. Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/potrero--5761582/support.

The Anglo Italian Podcast is back with our Serie A Gameweek 11 review — another wild weekend of drama, goals, and managerial chaos across Italy!

Scarica Revolut gratis con il mio link per ricevere un bonus di benvenuto di €20*: https://get.revolut.com/e9Jc/podcast1*Si applicano condizioni minimeLa domenica di Serie A dell'undicesima giornata, ci regala due nuove squadre al comando della classificia: Inter e Roma superano 2-0 Lazio e Udinese e sfruttano la sconfitta del Napoli a Bologna per prendersi il primo posto. A Bergamo è crisi Atalanta che cade 0-3 contro il Sassuolo mentre De Rossi e Vanoli si spartiscono un punto a testa all'esordio sulle panchine di Genoa e Fiorentina. Analisi e commento di Giuseppe Broggini ed Enrico Zambruno.Potrero, dove tutto ha inizio. Un podcast sul calcio italiano e internazionale. Su Como TV (https://tv.comofootball.com) nel 2025 potete seguire in diretta e gratuitamente le partite della Saudi Pro League, Saudi King's Cup, Supercoppa d'Arabia, Copa Libertadores, Copa Sudamericana, Recopa, Liga Profesional Argentina, Trofeo de Campeones argentino, Eredivisie, Coppa di Francia, Scottish Premiership, Coppa di Scozia, Scottish League Cup, Scottish Championship, Coppa di Portogallo, Supercoppa di Portogallo, HNL croata e tutti i contenuti di calcio italiano e internazionale on demand. Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/potrero--5761582/support.

Ampio commento sulla domenica di calcio in casa Genoa, dal pareggio per 2-2 alla prima di mister De Rossi alla vittoria del Genoa Women sul Parma in serata passando per il ritorno di Criscito (con vittoria) sulla panchina dell'Under 17. Buoncalcioatutti!

New Noah revealed… and he's having an affair with Sienna! Claire goes all the way with Holden… and back… to Kyle! Visit https://www.yrchat.com to chat with fun and friendly fans of The Young and the Restless. THIS WEEK: Ali’s Y&R Recap, The Weekly Y&R Polls, a “Who Said It” Quote Game, and Opening “The Chatterbox” […]

Commentiamo la bella vittoria dell'Atalanta contro l'Olympique Marsiglia, la Juventus che prende forma, un'Inter nervosetta e due cambi di panchina. Learn more about your ad choices. Visit megaphone.fm/adchoices

Maracanà con Marco Piccari e Stefano Impallomeni. Ospiti: Braglia:"La Lazio può fare lo scherzetto all'Inter" Orlando:" De Rossi può salvare il Genoa" De Paola:" La rosa dell'Inter la più completa. Lotito ha una visione provinciale"

Due inizi di stagione disastrosi, due cambi in panchina. Per acquistare il libro di Michele Tossani: https://incontropiede.it/lentini-lultimo-talento-del-filadelfia/ Hosted on Acast. See acast.com/privacy for more information.

Purgatory is not punishment. It's purification. In this episode, we explore the mystical heart of the Church's teaching on purgatory through the lens of love, unveiling, and divine transformation. Drawing on the Catechism, the early Fathers, and the voices of the mystics: St. Catherine of Genoa, St. John of the Cross, St. Thérèse of Lisieux, Julian of Norwich, and others—this reflection looks beyond fire and fear to reveal purgatory as the soul's unveiling before God.We'll uncover what the Catholic Church actually teaches about purgatory, what belongs to private revelation and opinion, and how the saints understood purification as the fire of divine love rather than punishment. Through this lens, purgatory becomes the final movement of theosis, the soul's slow adaptation to eternal light—the moment the veil begins to fall.

https://amzn.to/430RirJ GET YOUR COPY of F&F TODAY! AUDIOBOOK • EBOOK • PAPERBACK Available on Amazon & Everywhere Books Are Sold Signed editions and digital extras at https://www.RestlessForest.com Join me for the discussion: YouTube: https://www.youtube.com/@RestlessForestBooks Facebook: https://www.facebook.com/groups/restlessforestbooks Thank you for your support. … And now Y&R Chat: Claire and Holden get freaky!; Matt Clark is back?!; […]

La Juventus torna a vincere contro l'Udinese, mentre si aspetta l'ufficialità di Spalletti che è arrivato oggi alla Continassa per la firma. Intanto, Roma e Inter vincono, mentre Genoa e Fiorentina sono sempre più in crisi di risultati. Di tutto questo parliamo con Guido Vaciago direttore di Tuttosport e con Niccolò Ceccarini direttore di Tuttomercatoweb.Con Giorgio Sernagiotto di Cetilar Racing raccontiamo cosa è accaduto la scorsa settimana durante le Finali Mondiali Ferrari: sei intense giornate sulla pista del Mugello con le più celebri auto del Cavallino. Lì per noi c'era Gionata Ferroni che ha intervistato il pilota Ferrari Endurance Antonio Giovinazzi.

7 True Stories of Purgatory: The Purifying Fire (Ep. 486)Following last week's 7 Hallowed Stories of Holiness, this week we take you on a journey into other incredible, true stories of mercy. Purgatory is not God's punishment; it is His love, finishing its work.In this powerful special, we explore seven true stories that reveal the fire of mercy that purifies the soul for heaven. From the burned handprints preserved in Rome's Purgatory Museum to St. Catherine of Genoa's vision of love's refining flame; from St. Margaret Mary's suffering for a soul in need to Padre Pio's encounter with the “ghost” of a workman who waited for the Mass that would set him free—each story unveils a facet of God's justice made tender. (MANUSCRIPT)These are not ghost stories—they're grace stories.Listen as heaven's veil lifts and the saints remind us: love continues, prayer matters, and mercy never ends. Because the flames we fear are the same that free

Peter and Rob discuss Torino's dramatic late win against Genoa on Sunday, discuss a controversial Guesstafson moment and look ahead to Wednesday's match against Bologna - as Toro have an opportunity to win three league games in a row for the first time in 2,462 days. Hosted on Acast. See acast.com/privacy for more information.

A weary King Kull gazes into the forbidden mirrors of Tuzun Thune, seeking wisdom beyond mortal grasp. But in those shifting reflections lies a peril far greater than any enemy he's ever faced. The Mirrors of Tuzun Thune by Robert E. Howard. That's next on The Lost Sci-Fi Podcast.Quick heads-up: our brand-new Lost Sci-Fi Weekly newsletter launches this Monday, October 27. Tap the link in the description or visit LostSciFi.com to get it first.Newsletter - https://lostscifi.com/freeBefore there was Conan, there was King Kull—a brooding, introspective warrior-king from the ancient, drowned kingdom of Valusia. Created by Robert E. Howard, Kull first appeared in The Shadow Kingdom in 1929, one of the earliest true “sword and sorcery” tales.Howard wrote only a handful of complete Kull stories, but they stand among his most thoughtful and dreamlike works. The best known are The Shadow Kingdom, Kings of the Night, and today's story, The Mirrors of Tuzun Thune—a haunting story about the peril of looking too deeply into one's own reflection.You might remember the 1997 movie Kull the Conqueror — starring Kevin Sorbo (of Hercules fame) — which is the only movie explicitly featuring Kull. It was supposed to be a Conan the Barbarian sequel but was reworked into a Kull story when rights issues arose.We will find our story on page 367 in Weird Tales magazine in September 1929, The Mirrors of Tuzun Thune by Robert E. Howard…Next on The Lost Sci-Fi Podcast, A proud young exile meets a storm-working dwarf on a desolate Genoa shore — and in a single Faust-like bargain barters more than he understands. A metamorphosis so literal and so damning it cannot be untold. Or forgotten! Transformation by Mary Shelley.Rise - http://bit.ly/45So7Yr☕ Buy Me a Coffee https://www.buymeacoffee.com/scottsVDiscord - https://discord.gg/EXrY7UHTFacebook - https://www.facebook.com/TheLostSciFiPodcastTwitter - https://x.com/LostSciFiPodInstagram - https://www.instagram.com/lostscifiguy❤️ ❤️ Thanks to All Our Listeners Who Bought Us a Coffee$200 Someone$100 Tony from the Future$75 James Van Maanenberg$50 MizzBassie, Anonymous Listener$25 Someone, Eaten by a Grue, Jeff Lussenden, Fred Sieber, Anne, Craig Hamilton, Dave Wiseman, Bromite Thrip, Marwin de Haan, Future Space Engineer, Fressie, Kevin Eckert, Stephen Kagan, James Van Maanenberg, Irma Stolfo, Josh Jennings, Leber8tr, Conrad Chaffee, Anonymous Listener$15 Every Month Someone$15 Someone, Carolyn Guthleben, Patrick McLendon, Curious Jon, Buz C., Fressie, Anonymous Listener$10 Anonymous Listener$5 Every Month Eaten by a Grue$5 Denis Kalinin, Timothy Buckley, Andre'a, Martin Brown, Ron McFarlan, Tif Love, Chrystene, Richard Hoffman, Anonymous ListenerPlease participate in our podcast survey https://podcastsurvey.typeform.com/to/gNLcxQlk Hosted on Acast. See acast.com/privacy for more information.

Nick and Kyle unravel the Noah mystery; Mariah’s confession; Tessa and Daniel kiss!; Danny and Christine’s bach party; and Phyllis steals Cane’s AI! PLUS: The Weekly Y&R Chat Poll, “Who Said It” Game, and Opening “The Chatterbox” to Read YOUR Comments! Sign up to receive private e-mail updates from me: https://www.yrchat.com/storylines Why not pick up […]

Senior Landon Knigge rushed for a single-game school-record 447 yards and scored five touchdowns to lead Dixon to a 58-20 win over Genoa-Kingston in the regular-season finale Friday night at A.C. Bowers Field.Become a supporter of this podcast: https://www.spreaker.com/podcast/friday-night-drive--3534096/support.

The tragic fire at Grenfell Tower in west London demanded new ways of thinking about professionalism and ethics in the engineering sector. However, since that awful night in 2017, which saw the loss of 72 lives, fatal incidents and near misses have continued to happen: in Genoa, in Toddbrook, in Miami, and on many more... The post #349 Never Again: Embedding Safety in Engineering first appeared on Engineering Matters.

Join Matt and Jake as they talk you through the 7th Serie A Matchday of the 25/26 Season! Not that many goals this week with a quadruple 0-0 draw in the lineup of matches, but still so much to talk about, so make sure to listen all the way through!Timestamps1:16 Intro and Rundown 5:18 Goal Of the Week 12:29 Milan 2-1 Fiorentina 31:30 Roma 0-1 Inter 48:23 Como 2-0 Juve 1:15:28 Torino 1-0 Napoli 1:16:36 Atalanta 0-0 Lazio 1:27:22 Cagliari 0-2 Bologna 1:36:28 Cremonese 1-1 Udinese 2:05:23 Lecce 0-0 Sassuolo 1:53:12 Genoa 0-0 Parma 1:51:44 Pisa 0-0 Verona 2:09:20 Wisdom with the Wank 2:13:34 Pride of Indonesia Segment 2:16:20 OutroBecome a patreon: ⁦https://patreon.com/Serieaspotlight?⁩utm_medium=unknown&utm_source=join_link&utm_campaign=creators hare_creator&utm_content=copyLinkSpecial Shoutout to our Media Partners Benevo Bid - Check out their collection here; ⁦https://benevobid.com/⁩#acmilan #inter #juventus #torino #napoli #atalanta #bologna #fiorentina #roma #lazio #lecce #cagliari #udinese #monza #venezia #como #hellasverona #parma #empoli #genoa #football #soccer #footballpodcast #podcast PatreonYoutube: ⁦https://www.youtube.com/@serieaspotlight⁩Instagram: ⁦https://www.instagram.com/serieaspotlight/⁩Twitter: ⁦https://x.com/SerieASpotlight?⁩

Peter and Rob look back on Torino's shock 1-0 victory against Napoli on Saturday evening and preview Toro's next match against Genoa on Sunday. Hosted on Acast. See acast.com/privacy for more information.

Perché le squadre di Serie A non segnano più come una volta e la bellezza delle posizioni medie di Genoa-Parma.

A new Noah mystery!; Victoria and Nate get ‘friendly’; Kyle crashes Claire’s LA vacay; Phyllis touches Cane’s chest for a really long time; Danny and Christine pre-wedding preview; Tessa the Queen of Hearts; and Sally tells Billy the truth about Jill’s funding. PLUS: The Weekly Y&R Chat Poll, “Who Said It” Game, and Opening “The […]

Jaiden Lee had four touchdowns as Genoa-Kingston blew out Rock Falls, and Hiawatha fell to PoloBecome a supporter of this podcast: https://www.spreaker.com/podcast/friday-night-drive--3534096/support.

Couples therapy for Michael and Lauren; Daniel deep in love; Previews from L.A.; Jack and Diane team up against Victor!; Jill defends Cane; and We need to talk about Lily. PLUS: The Weekly Y&R Chat Poll, “Who Said It” Game, and Opening “The Chatterbox” to Read YOUR Comments! Sign up to receive private e-mail updates […]

Next Monday is Columbus Day. Or should it be Indigenous People's Day? According to the historian Matthew Restall we should be celebrating both Columbus and Indigenous People on Monday. The author of the timely The Nine Lives of Christopher Columbus, Restall places Genoa's most famous sailor as a prisoner of history - endlessly protean to reflect each era's changing values. The many lives of Columbus, then, is a mirror of how we have thought differently about him over the last 500 years. As history's greatest saint and sinner, Christopher Columbus might be the ultimate Rorschach test. Tell me what you'll be celebrating next Monday and I'll tell you who you are. Happy hols!1. Columbus Was a “Manic Narcissist” Who Believed He Was God's Agent Restall discovered Columbus wasn't likable—he descended into believing he was divinely chosen and could even be found in the Old Testament. This grandiosity was partly his undoing as a colonial administrator.2. Columbus Failed as a Colonizer and Administrator Unlike the conquistadors who came after him, Columbus lacked political and diplomatic skills. He was “just a sailor”—son of a weaver, grandson of a cheesemaker—and Spanish authorities quickly sidelined him. He died in 1506, only 13 years after his first voyage, with a declining reputation.3. The Columbus Day Debate Is About Different Columbuses Italian-Americans defend a 19th/20th century “Italian-American Columbus”—a symbol of immigrant achievement—while Indigenous Peoples' Day supporters condemn the “historic Columbus” who began a colonization process that killed 70-90% of indigenous populations within a century. These groups are talking past each other about entirely different figures.4. Conquistadors Were “Armed Entrepreneurs” Running Investment Companies Spanish conquistadors functioned like venture capital firms—assembling ships, soldiers, and supplies as investments, seeking returns through plunder and enslaved people, then winning authority positions to generate more profit while paying a 20% tax to the crown.5. Columbus's One Success: Founding a Noble Dynasty That Still Exists Despite his failures, Columbus achieved his main ambition—establishing an aristocratic dynasty. The title “Admiral of the Ocean Sea” granted in 1493 is still held today by the 20th admiral, a Spanish naval officer and businessman named Don Cristóbal Colón.Keen On America is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit keenon.substack.com/subscribe

La giornata di campionato si è chiuso con un noioso 0-0 tra Juventus e Milan. Si sarà annoiato anche il nostro convocato Nanu Galderisi a guardarla in tv? Il Napoli non molla la vetta della classifica grazie alla vittoria in rimonta sul Genoa. Ne parliamo con Massimo Ugolini che ha raccontato la partita da bordocampo per Sky Sport. Zitta zitta, in vetta si trova anche la Roma di Gasperini che ieri ha battuto una Fiorentina sempre più in crisi: "il momento è Viola scuro", parola di Dario Baldi oggi in studio con noi.

Jill boards the Cane train; Victor and Jack team up; Lauren busts Michael; Claire breaks up with Kyle; Audra asks Nate for forgiveness; Sally tries to saves the day; and Tessa tells Sharon she’s off on a mission! PLUS: The Weekly Y&R Chat Poll, “Who Said It” Game, and Opening “The Chatterbox” to Read YOUR […]

Trump declares war on American cities and the “enemy within” / Netanyahu pledges to violate Gaza “peace” plan just hours after its announcement / Dockworkers in Genoa and Livorno block Israeli arms shipment, as mass protests denounce genocide in Gaza

Loral Langemeier is a six-time New York Times bestselling author, world-renowned financial expert, and founder of Integrated Wealth Systems. With over 20 years of experience, she has mentored thousands of entrepreneurs and investors, built multimillion-dollar companies, and partnered with legends like Bob Proctor and Robert Kiyosaki. Known as “The Millionaire Maker,” Loral specializes in teaching people how to sequence their wealth and create financial independence through real estate, business, and smart investing strategies.     Make sure to download our free guide, 7 Questions Every Passive Investor Should Ask, here.     Key Takeaways Sequencing your wealth: doing the right thing at the right time. The importance of mentors and surrounding yourself with the right team. Why databases and consistent communication are critical assets for raising capital. Real estate investors often make mistakes by chasing deals without having capital and credit lined up. Debt can be a powerful tool—being in “good debt” is essential to scale quickly.     Topics From Farm Life to Financial Expert Grew up in Nebraska, discovered Think and Grow Rich early, and hired Bob Proctor at 21. Transitioned from exercise physiologist at Chevron to working with the Rich Dad team as master distributor of the Cashflow game. Building Wealth Through Sequencing Success comes from taking the right steps in the right order—structure before deals. Real estate investors fail when they do the right things at the wrong time. The Power of Mentorship and Team Mentors open doors, but you must provide value and take action. Success is built with a strong, trusted team—not by going solo. Raising Millions Through Databases Used her database of 18,000 people to raise $16M for projects in Oklahoma. Consistent communication and investor education are essential for long-term success. Debt as a Wealth Tool Don't fear debt—leverage it wisely for higher returns. Millionaires use “good debt” to accelerate wealth, not avoid it.